Combined modality therapy for Stage IIIMO non-small cell lung cancer. A five-year experience.

Abstract

Between 1975 and 1980, 101 patients with inoperable Stage IIIMO non-small cell lung carcinoma were entered into combined radiotherapy and chemotherapy trials at Michael Reese Hospital and University of Chicago Hospital. Sixty-four percent of the patients responded. Median survival for all patients was 8.8 months. Responders survived 13.7 months and… (More)

Topics

Cite this paper

@article{Madej1984CombinedMT, title={Combined modality therapy for Stage IIIMO non-small cell lung cancer. A five-year experience.}, author={Pawel Madej and J D Bitran and Harvey M. Golomb and Piotr Hoffman and Thomas Demeester and R K Desser and Rachna Kaul and V. Raghavan and Sarah Newman and Consuelo Skosey}, journal={Cancer}, year={1984}, volume={54 1}, pages={5-12} }